clioquinol has been researched along with Cognition Disorders in 9 studies
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.
5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
Excerpt | Relevance | Reference |
---|---|---|
" Six serious adverse events (acute coronary syndrome, major depression, pneumonia, suicide attempt, viral infection, and worsening of Huntington's disease) occurred in five participants in the PBT2 250 mg group, three (fall with subdural haematoma, suicide attempt, and hospital admission for stabilisation of Huntington's disease) occurred in two participants in the PBT2 100 mg group, and one (increasing aggression) occurred in a participant in the placebo group." | 2.80 | Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. ( , 2015) |
" The present study was designed to investigate the effect of metal ionophores on long term administration of zinc in D-galactose induced senescent mice." | 1.43 | Possible role of metal ionophore against zinc induced cognitive dysfunction in D-galactose senescent mice. ( Bharti, K; Majeed, AB; Prakash, A, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (22.22) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (77.78) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adlard, PA | 3 |
Sedjahtera, A | 2 |
Gunawan, L | 1 |
Bray, L | 1 |
Hare, D | 2 |
Lear, J | 1 |
Doble, P | 2 |
Bush, AI | 4 |
Finkelstein, DI | 3 |
Cherny, RA | 1 |
Langbehn, DR | 1 |
Parncutt, J | 1 |
Lal, V | 1 |
James, S | 1 |
Hare, DJ | 1 |
Billings, JL | 1 |
Nurjono, M | 1 |
Arthofer, E | 1 |
George, S | 1 |
Culvenor, JG | 1 |
Bharti, K | 1 |
Majeed, AB | 1 |
Prakash, A | 1 |
Faux, NG | 1 |
Ritchie, CW | 1 |
Gunn, A | 1 |
Rembach, A | 1 |
Tsatsanis, A | 1 |
Bedo, J | 1 |
Harrison, J | 1 |
Lannfelt, L | 1 |
Blennow, K | 1 |
Zetterberg, H | 1 |
Ingelsson, M | 1 |
Masters, CL | 1 |
Tanzi, RE | 1 |
Cummings, JL | 1 |
Herd, CM | 1 |
Buchanan, DS | 1 |
Ferrier, TM | 1 |
Eadie, MJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease[NCT01590888] | Phase 2 | 109 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Total Behavioural score from the Unified Huntington Disease Rating Scale. The behavioural assessment measures the frequency and severity of symptoms related to affect, thought content and coping styles. The total behaviour score is the sum of all responses, with scale range of 0 to 8. Higher scores on the behaviour assessments indicate more severe disturbance than lower scores. (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | units on a scale (Mean) |
---|---|
PBT2 250mg | -2.3 |
PBT2 100mg | 3.0 |
Sugar Pill | 0.7 |
Biomarkers assessed primarily with mutant huntingtin protein, normalised to lysate protein concentrations, as a change from baseline. (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | ratio (Mean) |
---|---|
PBT2 250mg | 1.97 |
PBT2 100mg | 0.14 |
Sugar Pill | -1.72 |
Biomarkers assessed primarily with soluble huntingtin protein, normalised to lysate protein concentrations, as a change from baseline. (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | mg/mL (Mean) |
---|---|
PBT2 250mg | -3.18 |
PBT2 100mg | -2.09 |
Sugar Pill | -3.07 |
Biomarkers assessed primarily with plasma selenium as a change from baseline. (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | ug/L (Mean) |
---|---|
PBT2 250mg | 1.3 |
PBT2 100mg | -6.3 |
Sugar Pill | 2.0 |
Measure of the structural brain volume as assessed by the left caudate volume. (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | mm^3 (Mean) |
---|---|
PBT2 250mg | 50.0 |
PBT2 100mg | 27.5 |
Sugar Pill | -170.5 |
Measure of whole brain iron concentrations. (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | mm^3 (Mean) |
---|---|
PBT2 250mg | 0.0029 |
PBT2 100mg | 0.0067 |
Sugar Pill | 0.0098 |
"Trail Making Test Part B was assessed by the number of seconds to complete the test (from 0 to 240 seconds).~The Trails Making Test Part B actual change from baseline at Week 26 was analysed." (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | seconds (Mean) |
---|---|
PBT2 250mg | -6.3 |
PBT2 100mg | 12.8 |
Sugar Pill | 8.9 |
"Total Functional Capacity (TFC) assessment was based on an individual's ability to perform common daily tasks. TFC score range was 0 to 13.~Higher scores on the function scales indicate better functioning than lower scores." (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | units on a scale (Mean) |
---|---|
PBT2 250mg | 1.1 |
PBT2 100mg | 1.3 |
Sugar Pill | 1.3 |
Global function was assessed by the Investigator using the clinical global impression (CGI) scale which included assessing the severity of illness and global improvement and calculating the efficacy index for each participant. The efficacy index aims to relate therapeutic effects to reported side effects as assessed by the Investigator (range from 0 [marked improvement and no side effects] to 4 [unchanged or worse] and side effects outweigh therapeutic effects) and is calculated for each participant by dividing the therapeutic effect score by the side effects score. An improvement is reflected by CGI scale Efficacy Index values >1. (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | ratio (Mean) |
---|---|
PBT2 250mg | 1.313 |
PBT2 100mg | 1.276 |
Sugar Pill | 1.176 |
Total motor score calculated from the Unified Huntington Disease Rating Scale - Motor Function. The motor section of the UHDRS assesses motor features of HD with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor impairment scores is the sum of all the individual motor ratings, with higher scores indicating more severe motor impairment than lower scores. A maximum score of 60 is possible (range 0-60). (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | units on a scale (Mean) |
---|---|
PBT2 250mg | -0.7 |
PBT2 100mg | 1.3 |
Sugar Pill | -1.3 |
Biomarkers assessed primarily with 8-hydroxy-2'-deoxyguanosine, normalised to creatinine concentrations, as a change from baseline. (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | ng/mL (Mean) |
---|---|
PBT2 250mg | -0.4258 |
PBT2 100mg | 0.0832 |
Sugar Pill | 35.5302 |
As measured by the total number of participants in each dose group who reported at least one adverse events during the study, (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | participants (Number) |
---|---|
PBT2 250mg | 32 |
PBT2 100mg | 30 |
Sugar Pill | 28 |
Cognition composite z-scores were calculated for each participant. The composite scores were defined as the mean of the individual z-scores for the various cognition assessments. The Main Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test and Stroop Word Reading Test. The Exploratory Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test, Stroop Word Reading Test and Speeded Tapping test. The Executive Function Composite z-score was calculated from Category Fluency Test and Trail Making Test Part B. There is no unit of measure for the z score as it is the pure number calculated from the SD from the mean. A higher z score indicates an improvement. (NCT01590888)
Timeframe: Baseline to 26 weeks
Intervention | z score (Mean) | ||
---|---|---|---|
Main Composite z-score | Exploratory Composite z-score | Executive Function z-score | |
PBT2 100mg | -0.0413 | -0.0287 | -0.1026 |
PBT2 250mg | 0.0592 | 0.0530 | 0.2274 |
Sugar Pill | -0.0194 | -0.0144 | 0.0553 |
2 trials available for clioquinol and Cognition Disorders
Article | Year |
---|---|
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Biomarkers; Clioquinol; Cognition Disorders; Double-Blind Method; Female; Humans; Huntington | 2015 |
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Area Under Curve; Australia; Clioquinol; Cognition Disorde | 2010 |
7 other studies available for clioquinol and Cognition Disorders
Article | Year |
---|---|
A novel approach to rapidly prevent age-related cognitive decline.
Topics: Aging; Animals; Behavior, Animal; Biomarkers; Cell Count; Clioquinol; Cognition Disorders; Dendritic | 2014 |
Criteria for success in safety and tolerability trials.
Topics: Clioquinol; Cognition Disorders; Female; Humans; Huntington Disease; Male | 2015 |
Metal chaperones prevent zinc-mediated cognitive decline.
Topics: Analysis of Variance; Animals; Carrier Proteins; Cation Transport Proteins; Clioquinol; Cognition Di | 2015 |
Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice.
Topics: alpha-Synuclein; Animals; Brain; Clioquinol; Cognition Disorders; Disease Models, Animal; Explorator | 2016 |
Possible role of metal ionophore against zinc induced cognitive dysfunction in D-galactose senescent mice.
Topics: Administration, Oral; Aging; Amyloid beta-Peptides; Animals; Clioquinol; Cognition Disorders; Dose-R | 2016 |
Iatrogenic causes of neurologic disorders: part 1. Affect, convulsions, and encephalopathies.
Topics: Affective Symptoms; Aged; Antiparkinson Agents; Brain Diseases; Clioquinol; Cognition Disorders; Hum | 1978 |
Clioquinol encephalopathy.
Topics: Adult; Brain Diseases; Clioquinol; Cognition Disorders; Female; Headache; Humans; Male; Memory Disor | 1973 |